Using AI Systems to Optimize the Clinical Outcome of Stroke Patients
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 11, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can improve rehabilitation for stroke patients. With the increasing number of people affected by strokes, especially in Hong Kong, the goal is to provide better, personalized rehabilitation options that can help patients regain their independence more effectively. By using advanced AI technology, researchers hope to predict which rehabilitation methods will work best for individual patients based on various assessments, including brain scans and muscle activity tests.
To participate in this trial, individuals must be aged 65 to 80 and have experienced a first-time stroke within the last 1 to 6 months, resulting in moderate to severe difficulty using one arm. They should be able to follow instructions and provide consent, and their muscle activity must meet certain criteria to ensure the rehabilitation techniques can be successful. Participants can expect to undergo an evaluation to determine their rehabilitation needs, and they will receive tailored treatment that may include usual care, stimulation exercises, robotic training, or acupuncture. This study aims not only to help current patients but also to pave the way for innovative rehabilitation strategies in the future.
Gender
ALL
Eligibility criteria
- IInclusion Criteria:
- • Age 65-80
- • 1-6 months after onset of a first-time unilateral stroke rostral to midbrain
- • Moderate-to-severe motor impairment of one upper limb (Fugl-Meyer Assessment for Upper Extremity of 10-50 out of 66);
- • Able to provide written informed consent;
- • Detectable electromyographic (EMG) activities in flexor digitorum-flexor carpi radialis and extensor digitorum-extensor carpi ulnaris muscle groups, with EMG from each muscle group exceeding 3 standard deviations above baseline mean. This last criterion is essential for successful NMES training
- Exclusion Criteria:
- • Unconscious or bed-bound;
- • Uncontrollable diabetes;
- • Anticipated non-adherence to treatment schedule;
- • On cardiac pacemaker;
- • Other severe comorbidities (heart/kidney failure, deranged liver function).
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported